CDEK
← All drugs Report issue

cemdisiran

Nucleic acidexperimental

Clinical trial activity

16 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
12
Phase 3
6
Phase 4
0

Earliest trial started Jan 1, 2015 (NCT02352493)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • aln-cc5

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07154745Phase 3Dec 19, 2025Regeneron
NCT06541704Phase 3Oct 28, 2024Regeneron
NCT06479863Early Phase 1 (Phase 1)Aug 8, 2024Austin Neuromuscular Center, Regeneron
NCT05744921Phase 3Mar 7, 2023Regeneron
NCT05133531Phase 3Jul 31, 2022Regeneron
NCT05131204Phase 3Mar 31, 2022Regeneron
NCT05070858Phase 3Sep 30, 2021Regeneron
NCT04940364Phase 1Aug 4, 2021Regeneron
NCT04811716Phase 2Jul 28, 2021Regeneron
NCT04888507Phase 2Jul 8, 2021Regeneron
NCT04601844Phase 1Nov 16, 2020Alnylam Pharmaceuticals, Regeneron
NCT03999840Phase 2Sep 30, 2019Alnylam Pharmaceuticals, Mario Negri Institute
NCT03841448Phase 2Apr 24, 2019Alnylam Pharmaceuticals
NCT03303313Phase 2Sep 19, 2017Alnylam Pharmaceuticals
NCT02352493Phase 1/Phase 2 (Phase 2)Jan 1, 2015Alnylam Pharmaceuticals
NCT06028594N/A—Regeneron
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RegeneronFor profit121142020
Alnylam PharmaceuticalsFor profit5322015
Austin Neuromuscular CenterAcademic/Hospital1112024
Mario Negri InstituteAcademic/Hospital1112019
4 organizations
Page 1 / 1